The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The United States Food and Drug Administration has approved a rituximab biosimilar candidate developed by pharmaceutical company Dr. Reddy’s Laboratories.
Dr. Ponce outlines bone health parameters for axatilimab, a high-affinity anti-CSF-1R monoclonal antibody.
ASCO’s first guideline on ctDNA testing in solid tumors and lymphoma was published by Christina Lockwood, PhD, head of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center, in the Journal of Clinical Oncology in June.
The panel discussed combining trispecifics with mezigdomide, noting the strong activity and improved tolerability of targeting BCMA and CD38. They also discussed how mezigdomide might reverse T-cell exhaustion, while cautioning that careful treatment sequencing is necessary because mezigdomide is highly immune-activating.
From EHA 2026, Dr. Komrokji shares the latest research in MDS, and his thoughts on what is next in the field.
Held annually in São Paulo, SOHO Brazil is part of the SOHO Ambassador Program, which supports regional meetings around the world to expand education in hematologic oncology.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
